Pharmaceutical News

RSS

Promising families of drugs combat the spread of tumors in different ways

Pharmaceutical companies seeking to design more effective cancer chemotherapy agents may have an easier road ahead than was previously believed.

9 Aug 2004

Total global market for oligonucleotides is likely to grow from USD 340.0 million in 2003 to USD 776.0 million in 2010

Poised on the brink of phenomenal growth, the oligonucleotides market offers a plethora of opportunities to the enterprising investor. Recent analysis by Frost & Sullivan estimates that the total global market for oligonucleotides is likely to grow from USD 340.0 million in 2003 to USD 776.0 million in 2010.

9 Aug 2004

Promising new cancer drug, Nanotax

A Lawrence company that uses patented technology created at the University of Kansas to improve the effectiveness of drugs has won a $100,000 National Institutes of Health grant to support further testing of the company's promising new cancer drug, Nanotax.

5 Aug 2004

Approval of Cymbalta for treatment of major depressive disorder

The U.S. Food and Drug Administration has approved Cymbalta® (duloxetine HCl; pronounced SIM-BALL-TA), judging it a safe and effective treatment for major depressive disorder, Eli Lilly and Company have announced.

5 Aug 2004

Approval of fixed-dose combination treatments for HIV-1 infection

The Food and Drug Administration has announced the approvals of Epzicom (abacavir/lamivudine) and Truvada (tenofovir disoproxil/emtricitabine), two fixed-dose combination treatments for HIV-1 infection.

5 Aug 2004

Approval of cholesterol-lowering therapy Lipitor for the prevention of cardiovascular disease

Pfizer has announced that the U.S. Food and Drug Administration has approved its cholesterol-lowering therapy Lipitor® (atorvastatin calcium) for the prevention of cardiovascular disease by reducing heart attack risk in people with normal to mildly elevated cholesterol levels who have other cardiovascular risk factors.

5 Aug 2004

Michigan settlement with pharmaceutical manufacturer Schering Plough

Michigan Attorney General Mike Cox announced today a settlement with pharmaceutical manufacturer Schering Plough over its underpayment of Medicaid Drug Rebates on the antihistamine drug Claritin, netting more than $2.6 million for Michigan’s Medicaid program.

3 Aug 2004

Third of heart failure patients face increased risk of death because they do not receive an angiotensin-converting enzyme (ACE) inhibitor

Overwhelming evidence accumulated during almost 20 years of clinical experience has established the benefits of this drug, which blocks the harmful effects of angiotensin, a substance that causes blood vessels to narrow, said the study authors.

3 Aug 2004

CV Therapeutics initiates approval-enabling trial of drug to treat chronic angina

CV Therapeutics has announced that it has initiated an approval-enabling study of Ranexa, which, if successful, could support approval of Ranexa for the treatment of chronic angina in a restricted patient population.

3 Aug 2004

FDA approval for mint flavor nicotine gum

Watson Pharmaceuticals announced today that it has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application for nicotine polacrilex gum, mint flavor, in the 2 and 4 mg strengths.

3 Aug 2004

Aventis ships its influenza vaccine, Fluzone

Aventis began to ship its influenza vaccine (Fluzone(R), Influenza Virus Vaccine) today, meeting the company's goal to provide Fluzone vaccine to customers to allow health-care providers to plan successful immunization programs for the upcoming influenza season.

3 Aug 2004

FDA has granted orphan drug designation to Myogen's ambrisentan, for the treatment of pulmonary arterial hypertension

Myogen has announced that the United States Food and Drug Administration has granted orphan drug designation to ambrisentan for the treatment of pulmonary arterial hypertension (PAH).

3 Aug 2004

Metabasis Therapeutics announces multi-center Phase 2 study to evaluate the orally administered antiviral compound remofovir mesylate

Metabasis Therapeutics has announced the initiation of a multi-center, multi- national Phase 2 study to evaluate the orally administered antiviral compound remofovir mesylate in chronic hepatitis B (HBV) infected patients.

3 Aug 2004

New Drug Application with the U.S. Food and Drug Administration for Tarceva

OSI Pharmaceuticals and Genentech have announced that OSI completed the submission of a New Drug Application with the U.S. Food and Drug Administration for Tarceva (erlotinib HCl),

3 Aug 2004

FDA approves two fixed-dose combination treatments for HIV-1 infection

The Food and Drug Administration has announced approved Epzicom (abacavir/lamivudine) and Truvada (tenofovir disoproxil/emtricitabine), two fixed-dose combination treatments for HIV-1 infection.

2 Aug 2004

Schering-Ploug will return more than $9 million to the Texas Medicaid program for the company’s fraudulent reporting of prices for drug Claritin

Texas Attorney General Greg Abbott has announced a settlement among Texas and other states with pharmaceutical giant Schering-Plough Inc. that will return more than $9 million to the Texas Medicaid program for the company’s fraudulent reporting of prices for the antihistamine drug Claritin.

2 Aug 2004

European recommended approval of Remicade for treatment of psoriatic arthritis

Committee for Medicinal Products for Human Use of the European Agency for the Evaluation of Medicinal Products has issued a positive opinion recommending approval of expanded labeling for REMICADE(R) (infliximab), in combination with methotrexate, for treatment of active and progressive psoriatic arthritis (PsA) in patients who have responded inadequately to disease modifying anti- rheumatic drugs (DMARDs).

2 Aug 2004

Requip significantly reduces periodic leg movements in patients with restless legs syndrome

New data published in the August issue of SLEEP shows that patients with primary Restless Legs Syndrome (RLS) and with periodic leg movements during sleep (PLMS), have fewer awakenings resulting from involuntary kicks when treated with GlaxoSmithKline's Requip (ropinirole HCl).

2 Aug 2004

Schering Plough to reimburse Washington's Medicaid program $3.57 million in Claritin case

Pharmaceutical manufacturer Schering Plough will reimburse Washington's Medicaid program $3.57 million in a nationwide settlement of allegations the drug maker failed to offer state Medicaid programs its best price for the popular antihistamine drug Claritin.

31 Jul 2004

Warning for counterfeit drugs simvastatin and carisoprodol recently imported from Mexico

The U.S. Food and Drug Administration has issued a public warning regarding counterfeit versions of the drugs simvastatin and carisoprodol that have recently been imported from Mexico to the U.S.

31 Jul 2004

Pharmaceutical News

Promising families of drugs combat the spread of tumors in different ways

Total global market for oligonucleotides is likely to grow from USD 340.0 million in 2003 to USD 776.0 million in 2010

Promising new cancer drug, Nanotax

Approval of Cymbalta for treatment of major depressive disorder

Approval of fixed-dose combination treatments for HIV-1 infection

Approval of cholesterol-lowering therapy Lipitor for the prevention of cardiovascular disease

Michigan settlement with pharmaceutical manufacturer Schering Plough

Third of heart failure patients face increased risk of death because they do not receive an angiotensin-converting enzyme (ACE) inhibitor

CV Therapeutics initiates approval-enabling trial of drug to treat chronic angina

FDA approval for mint flavor nicotine gum

Aventis ships its influenza vaccine, Fluzone

FDA has granted orphan drug designation to Myogen's ambrisentan, for the treatment of pulmonary arterial hypertension

Metabasis Therapeutics announces multi-center Phase 2 study to evaluate the orally administered antiviral compound remofovir mesylate

New Drug Application with the U.S. Food and Drug Administration for Tarceva

FDA approves two fixed-dose combination treatments for HIV-1 infection

Schering-Ploug will return more than $9 million to the Texas Medicaid program for the company’s fraudulent reporting of prices for drug Claritin

European recommended approval of Remicade for treatment of psoriatic arthritis

Requip significantly reduces periodic leg movements in patients with restless legs syndrome

Schering Plough to reimburse Washington's Medicaid program $3.57 million in Claritin case

Warning for counterfeit drugs simvastatin and carisoprodol recently imported from Mexico

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News